Ongoing Trials & Criteria
Work with us to further our vision of improving research translation for better health outcomes for all. We welcome inquiries and engagement from patients, consumers and all health and medical researchers, clinicians and administrators.
Ongoing Trials & Criteria
Use of for Treating Adults With Acute Gout Flare
Site/Study Location
Tarzana
Protocol
OLT1177-08
Trail Details
Gout is a common and painful form of inflammatory arthritis caused by elevated levels of uric acid in the blood, leading to the formation of urate crystals in joints. Acute gout flares can cause sudden and severe pain, redness, and swelling, most commonly in the lower extremities. Current treatments may be insufficient or poorly tolerated by some patients, especially those with comorbidities. This clinical study investigates the safety and efficacy of OLT1177, a selective NLRP3 inflammasome inhibitor, in treating adults experiencing an acute gout flare.
Approximately 250 participants are expected to be enrolled. The primary objective is to evaluate the reduction in pain and inflammation associated with acute gout flares through targeted inhibition of the inflammatory cascade.
Inclusion Criteria
Age and Consent: Adults aged 18–75 who are capable of providing written informed consent.
Diagnosis: Confirmed diagnosis of gout with at least one documented acute flare in the past year.
Current Flare Status: Participants must be experiencing a qualifying acute gout flare at screening or randomization.
Pain Level: Moderate to severe pain in the affected joint, typically rated ≥5 on a numeric pain scale.
Compliance: Participants must be willing and able to comply with study procedures and follow-up schedules.
Exclusion Criteria
Secondary Arthritis: Presence of other inflammatory joint diseases, such as rheumatoid arthritis or psoriatic arthritis.
Infection or Septic Arthritis: Any active infection or suspected joint infection.
Kidney Impairment: Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m².
Hepatic Impairment: Elevated liver enzymes (ALT/AST >3x ULN) or known liver disease.
Recent Experimental Treatment: Use of any investigational drug within 30 days prior to screening.
NSAID or Steroid Contraindication: Known intolerance or medical contraindications to study-permitted anti-inflammatory rescue therapies.
Comorbid Conditions: Any uncontrolled comorbidities that could increase risk or interfere with study outcomes.
Substance Abuse: History of alcohol or drug abuse within the past 12 months.
Pregnancy and Nursing: Women who are pregnant, breastfeeding, or planning pregnancy during the study. Women of childbearing potential must use highly effective contraception.
Male Participants: Men with partners of childbearing potential must use condoms during the study and for a specified period thereafter, in accordance with the protocol.
Benefits of Participation
Participants may receive study-related care and medication at no cost.
Compensation may be provided for time and travel.
No personal health insurance is required to participate.
Care will be provided by board-certified physicians and experienced clinical research staff.
Use of for Treating Adults With Moderate Alzheimer’s Disease
Site/Study Location
Tarzana
Protocol
SNK01-AD01
Trail Details
Alzheimer’s disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and functional impairment. Moderate Alzheimer’s is marked by increasing difficulty with daily tasks, language problems, and confusion about time or place. There is a significant need for therapies that can modify the course of the disease or improve cognitive function and quality of life.
This clinical trial investigates SNK01, now referred to as troculeucel, an autologous, enhanced Natural Killer (NK) cell therapy developed by NKGen Biotech, Inc., for its safety and potential efficacy in slowing or reversing disease progression in individuals with moderate Alzheimer’s disease.
Approximately 30 participants are expected to be enrolled in this Phase 2 randomized, double-blind clinical trial, with 20 receiving troculeucel and 10 receiving placebo. The primary objective is to evaluate the reduction in cognitive decline associated with moderate Alzheimer’s disease through targeted NK cell therapy.
Inclusion Criteria
Age and Consent: Adults aged 50–85 who are capable of providing informed consent or have a legally authorized representative who can do so.
Diagnosis: Documented diagnosis of moderate Alzheimer’s disease, typically supported by MMSE (Mini-Mental State Examination) scores between 10–20.
Brain Imaging: MRI or CT scan confirming Alzheimer’s-related neurodegenerative changes.
Stability: Must have been on a stable dose of Alzheimer’s medication (if any) for at least 3 months prior to screening.
Study Partner: Availability of a reliable caregiver or study partner who can assist with compliance and attend visits.
Exclusion Criteria
Other Dementias: Diagnosis of other types of dementia, such as vascular dementia or frontotemporal dementia.
Severe Psychiatric Illness: Major depression, schizophrenia, or any other psychiatric disorder that may confound assessments.
Recent Clinical Trial Participation: Enrollment in another investigational study within the last 30 days.
Uncontrolled Medical Conditions: Including unstable cardiovascular disease, severe renal or hepatic impairment, or active cancer.
Immunosuppressive Therapy: Use of chronic corticosteroids or other immunosuppressants.
Infections: Active systemic infections, including hepatitis B, hepatitis C, or HIV.
Allergy or Hypersensitivity: Known allergies to components of the cell therapy product.
Other Neurodegenerative Disorders: Such as Parkinson’s disease or Huntington’s disease.
Benefits of Participation
Participants may receive novel investigational cell therapy at no cost.
Comprehensive medical oversight by board-certified physicians and trained staff throughout the study.
Regular monitoring of cognitive function, safety labs, and health status.
Compensation may be provided for time and travel.
Participation contributes to advancing research in Alzheimer’s disease therapies.
Use of for Treating Adults With Obesity – Part B
Site/Study Location
Tarzana
Protocol
R1033-OB-228 – Part B
Trail Details
Obesity is a chronic metabolic condition characterized by excessive fat accumulation that presents a significant risk to health. It increases the likelihood of developing comorbidities such as type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. The global prevalence of obesity continues to rise, prompting urgent demand for innovative, effective, and sustainable treatment options.
This clinical trial, R1033-OB-228 – Part B, is sponsored by Regeneron Pharmaceuticals and conducted in partnership with ICON plc. The purpose of this Phase 2 study is to evaluate the safety, tolerability, and efficacy of R1033, an investigational therapy aimed at inducing meaningful weight loss in individuals with obesity.
The study will be conducted at a site in Tarzana under the direction of Principal Investigator Dr. Kalpesh Patel, with recruitment starting in 2024.
Inclusion Criteria
Age and Consent: Adults aged 18–75 capable of giving informed consent.
BMI Requirement: Body mass index (BMI) ≥30 kg/m², or ≥27 kg/m² with at least one obesity-related comorbidity (e.g., hypertension, dyslipidemia).
Weight Stability: No significant weight change (>5%) within 3 months prior to screening.
Lifestyle Stability: Stable dietary and physical activity patterns for at least 3 months.
Health Status: Medically stable without acute illness or uncontrolled chronic diseases.
Compliance: Willingness to adhere to study visits, procedures, and investigational product administration.
Exclusion Criteria
Type 1 Diabetes or Poorly Controlled Type 2 Diabetes: HbA1c >9% or requiring insulin therapy.
Recent Use of Anti-Obesity Agents: Use of weight loss medications or bariatric surgery within the past 6 months.
Major Cardiovascular Events: History of heart attack, stroke, or hospitalization for heart failure within 6 months.
Severe Liver or Kidney Dysfunction
Uncontrolled Hypertension: Blood pressure >160/100 mmHg at screening.
Eating Disorders: History of bulimia, anorexia nervosa, or other significant disordered eating.
Pregnancy and Lactation: Women who are pregnant, breastfeeding, or planning pregnancy during the study.
Substance Abuse: Recent or ongoing drug or alcohol abuse.
Participation in Another Trial: Investigational drug use within 30 days prior to screening.
Benefits of Participation
Participants may receive investigational treatment at no cost.
Frequent health monitoring and metabolic evaluations by board-certified medical professionals.
Compensation for time and travel may be provided.
Opportunity to contribute to the advancement of obesity treatments that may benefit others in the future.
Use of for Treating Adults With Obesity – Part B
Site/Study Location
Huntington Park
Protocol
R1033-OB-228 – Part B
Trail Details
Obesity is a chronic metabolic condition characterized by excessive fat accumulation that presents a significant risk to health. It increases the likelihood of developing comorbidities such as type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. The global prevalence of obesity continues to rise, prompting urgent demand for innovative, effective, and sustainable treatment options.
This clinical trial, R1033-OB-228 – Part B, is sponsored by Regeneron Pharmaceuticals and conducted in partnership with ICON plc. The purpose of this Phase 2 study is to evaluate the safety, tolerability, and efficacy of R1033, an investigational therapy aimed at inducing meaningful weight loss in individuals with obesity.
The study will be conducted at a site in Tarzana under the direction of Principal Investigator Dr. Kalpesh Patel, with recruitment starting in 2024.
Inclusion Criteria
Age and Consent: Adults aged 18–75 capable of giving informed consent.
BMI Requirement: Body mass index (BMI) ≥30 kg/m², or ≥27 kg/m² with at least one obesity-related comorbidity (e.g., hypertension, dyslipidemia).
Weight Stability: No significant weight change (>5%) within 3 months prior to screening.
Lifestyle Stability: Stable dietary and physical activity patterns for at least 3 months.
Health Status: Medically stable without acute illness or uncontrolled chronic diseases.
Compliance: Willingness to adhere to study visits, procedures, and investigational product administration.
Exclusion Criteria
Type 1 Diabetes or Poorly Controlled Type 2 Diabetes: HbA1c >9% or requiring insulin therapy.
Recent Use of Anti-Obesity Agents: Use of weight loss medications or bariatric surgery within the past 6 months.
Major Cardiovascular Events: History of heart attack, stroke, or hospitalization for heart failure within 6 months.
Severe Liver or Kidney Dysfunction
Uncontrolled Hypertension: Blood pressure >160/100 mmHg at screening.
Eating Disorders: History of bulimia, anorexia nervosa, or other significant disordered eating.
Pregnancy and Lactation: Women who are pregnant, breastfeeding, or planning pregnancy during the study.
Substance Abuse: Recent or ongoing drug or alcohol abuse.
Participation in Another Trial: Investigational drug use within 30 days prior to screening.
Benefits of Participation
Participants may receive investigational treatment at no cost.
Frequent health monitoring and metabolic evaluations by board-certified medical professionals.
Compensation for time and travel may be provided.
Opportunity to contribute to the advancement of obesity treatments that may benefit others in the future.
Use of for Treating Adults With Obesity – Part C
Site/Study Location
Tarzana
Protocol
R1033-OB-228 – Part C
Trail Details
Obesity is a growing global health concern, associated with increased risk of serious conditions such as cardiovascular disease, type 2 diabetes, and certain cancers. Current therapies offer varying degrees of effectiveness and tolerability, which has led to increasing demand for novel, long-term, and safe treatment options.
This clinical trial, R1033-OB-228 – Part C, is a Phase 2 extension of the broader R1033 obesity program led by Regeneron Pharmaceuticals, in collaboration with ICON plc as the CRO. The investigational therapy, R1033, is being evaluated for its potential to induce clinically meaningful weight loss and improve metabolic health in individuals with obesity.
Inclusion Criteria
Age: 18 to 75 years old.
BMI Requirement: ≥30 kg/m² or ≥27 kg/m² with at least one associated comorbidity (e.g., dyslipidemia, hypertension).
Weight Stability: Less than 5% weight change in the three months prior to screening.
Lifestyle: Consistent eating habits and physical activity levels over the last three months.
Medication Stability: No recent changes in chronic medications that affect weight.
Informed Consent: Must be able and willing to provide written informed consent and comply with study procedures.
Exclusion Criteria
Type 1 Diabetes or Poorly Managed Type 2 Diabetes: HbA1c >9% or insulin dependence.
Bariatric Surgery: History of weight loss surgery or planned procedures during the study period.
Unstable Medical Conditions: Uncontrolled hypertension, significant liver disease, severe renal impairment, or recent cardiovascular events.
Current Use of Anti-Obesity Drugs: Within the past 6 months.
Psychiatric Disorders: History of major depression or eating disorders that may interfere with participation.
Pregnancy and Breastfeeding: Females who are pregnant, lactating, or planning pregnancy during the study.
Substance Abuse: Active alcohol or drug abuse.
Recent Investigational Product Use: Within 30 days or five half-lives, whichever is longer, prior to screening.
Benefits of Participation
Access to investigational treatment (R1033) at no cost.
Comprehensive health assessments, including metabolic and cardiovascular risk monitoring.
Support from a dedicated research team, including frequent follow-up visits and lifestyle guidance.
Compensation may be provided for time and travel expenses.
Contribution to the development of innovative obesity therapies.
Use of for Treating Adults With Obesity – Part C
Site/Study Location
Huntington Park
Protocol
R1033-OB-228 – Part C
Trail Details
Obesity is a growing global health concern, associated with increased risk of serious conditions such as cardiovascular disease, type 2 diabetes, and certain cancers. Current therapies offer varying degrees of effectiveness and tolerability, which has led to increasing demand for novel, long-term, and safe treatment options.
This clinical trial, R1033-OB-228 – Part C, is a Phase 2 extension of the broader R1033 obesity program led by Regeneron Pharmaceuticals, in collaboration with ICON plc as the CRO. The investigational therapy, R1033, is being evaluated for its potential to induce clinically meaningful weight loss and improve metabolic health in individuals with obesity.
The study site is located in Tarzana, under the oversight of Principal Investigator Dr. Kalpesh Patel, with trial initiation beginning in 2025.
Inclusion Criteria
Age: 18 to 75 years old.
BMI Requirement: ≥30 kg/m² or ≥27 kg/m² with at least one associated comorbidity (e.g., dyslipidemia, hypertension).
Weight Stability: Less than 5% weight change in the three months prior to screening.
Lifestyle: Consistent eating habits and physical activity levels over the last three months.
Medication Stability: No recent changes in chronic medications that affect weight.
Informed Consent: Must be able and willing to provide written informed consent and comply with study procedures.
Exclusion Criteria
Type 1 Diabetes or Poorly Managed Type 2 Diabetes: HbA1c >9% or insulin dependence.
Bariatric Surgery: History of weight loss surgery or planned procedures during the study period.
Unstable Medical Conditions: Uncontrolled hypertension, significant liver disease, severe renal impairment, or recent cardiovascular events.
Current Use of Anti-Obesity Drugs: Within the past 6 months.
Psychiatric Disorders: History of major depression or eating disorders that may interfere with participation.
Pregnancy and Breastfeeding: Females who are pregnant, lactating, or planning pregnancy during the study.
Substance Abuse: Active alcohol or drug abuse.
Recent Investigational Product Use: Within 30 days or five half-lives, whichever is longer, prior to screening.
Benefits of Participation
Access to investigational treatment (R1033) at no cost.
Comprehensive health assessments, including metabolic and cardiovascular risk monitoring.
Support from a dedicated research team, including frequent follow-up visits and lifestyle guidance.
Compensation may be provided for time and travel expenses.
Contribution to the development of innovative obesity therapies.
Use of Investigational Novo Nordisk Compound for Treating Adults With Obesity or Metabolic Syndrome
Site/Study Location
Huntington Park
Protocol
EX6018-4758
Trail Details
Obesity and metabolic disorders continue to rise worldwide, increasing the risk for chronic conditions such as cardiovascular disease, type 2 diabetes, and liver disease. Novo Nordisk has developed a strong portfolio of GLP-1 and amylin analogues—such as semaglutide and cagrilintide—to address the unmet need for safe and effective weight loss and glycemic control.
EX6018-4758 is a clinical trial sponsored and conducted by Novo Nordisk, evaluating the safety and efficacy of an investigational treatment for adults with obesity or metabolic conditions. This Phase 2/3 trial aims to assess weight loss, metabolic improvements, and cardiovascular benefits over a defined study period.
Inclusion Criteria
Age: Adults aged 18–75.
BMI Requirement: ≥30 kg/m² or ≥27 kg/m² with comorbidities (e.g., hypertension, dyslipidemia, prediabetes).
Stable Medical Condition: No major changes in chronic medications or acute medical issues within 3 months prior to enrollment.
Willingness to Participate: Must provide informed consent and comply with study visits and procedures.
Lifestyle History: Documented history of unsuccessful weight loss attempts via diet and exercise.
Exclusion Criteria
Type 1 Diabetes or Uncontrolled Type 2 Diabetes
Recent Use of Anti-Obesity Medications: Use within 3 months prior to screening.
Prior Bariatric Surgery
Uncontrolled Hypertension or Cardiovascular Events within the last 6 months.
Significant Liver or Kidney Dysfunction
History of Pancreatitis or Medullary Thyroid Carcinoma
Pregnancy or Breastfeeding
Substance Abuse or Major Psychiatric Disorders
Use of GLP-1 or Amylin Analogs in the last 6 months.
Benefits of Participation
Access to cutting-edge therapy at no cost.
Frequent health monitoring and labs.
Board-certified medical oversight and support from a skilled research staff.
Travel and time compensation may be provided.
Contribute to advancing treatments for obesity and metabolic health.
Use of for Promoting Healing in Chronic Wounds
Site/Study Location
San Diego
Protocol
OI-24001
Trail Details
Chronic wounds such as diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers are a significant burden on both patients and healthcare systems. They are often slow to heal, prone to infection, and can lead to complications like amputation or systemic illness. Traditional treatments frequently fail to achieve durable closure.
OI-24001 is an investigational biologic therapy developed by OrganoGenesis, a company specializing in regenerative medicine and advanced wound care. This clinical trial aims to evaluate the safety and efficacy of OI-24001 in accelerating wound closure and tissue regeneration in patients with chronic, non-healing ulcers.
Inclusion Criteria
Adults aged ≥18 years
Presence of a chronic wound, including but not limited to:
Diabetic foot ulcers (DFUs)
Venous leg ulcers (VLUs)
Pressure ulcers (PUs)
Wound duration ≥4 weeks, but ≤12 months
Wound size within a specified range (e.g., 1–25 cm² depending on indication)
Adequate circulation to the affected limb as determined by clinical testing
Ability to comply with study visits, treatment regimen, and follow-up
Exclusion Criteria
Active infection in or around the target wound site
Osteomyelitis or bone exposure in the wound
Severe peripheral arterial disease or ankle-brachial index (ABI) outside inclusion range
Use of advanced wound therapies (e.g., growth factors, biologics) within 30 days prior
Autoimmune or immunosuppressive conditions affecting wound healing
Pregnancy or lactation
Participation in another clinical trial within 30 days prior to screening
Benefits of Participation
Access to cutting-edge regenerative treatment (OI-24001) at no cost
Regular wound assessments by board-certified specialists
Advanced diagnostics (vascular and microbial testing)
Travel and time compensation may be available
Close clinical monitoring, reducing the risk of complications
Use of AstraZeneca's in Adults With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease
Site/Study Location
Huntington Park
Protocol
D9441C00001
Trail Details
Use of Cleerly Imaging AI in Primary Prevention of Cardiovascular Events in At-Risk Asymptomatic Individuals
Inclusion Criteria
Adults aged ≥18 years
Documented history of atherosclerotic cardiovascular disease, including:
Prior myocardial infarction (MI)
Ischemic stroke
Peripheral arterial disease (PAD)
Diagnosed chronic kidney disease:
eGFR between 25 and 60 mL/min/1.73m², or
Moderate albuminuria (UACR ≥30 mg/g)
On stable background therapy, such as statins, RAAS blockers, or SGLT2 inhibitors
Willing and able to provide informed consent and comply with study procedures
Exclusion Criteria
Recent acute events such as MI, stroke, or unstable angina within 3 months of screening
Patients currently undergoing dialysis or with a kidney transplant
Severe hepatic impairment
Known hypersensitivity to investigational product
Active cancer, except non-melanoma skin cancers or other low-risk types
Uncontrolled hypertension (e.g., SBP >180 mmHg)
Pregnant or breastfeeding women
Current participation in another investigational trial
Benefits of Participation
Access to cutting-edge cardiovascular and renal therapy at no cost
Regular follow-up visits and comprehensive health monitoring
Care provided by a board-certified principal investigator and skilled clinical research staff
Travel and participation compensation may be available
Contribution to the development of therapies that can benefit millions of high-risk patients globally
Use of Cleerly Imaging AI in Primary Prevention of Cardiovascular Events in At-Risk Asymptomatic Individuals
Site/Study Location
Tarzana
Protocol
202302CPC
Trail Details
Cardiovascular disease (CVD) remains the leading cause of death globally, and many at-risk individuals—especially those with Type 2 diabetes, prediabetes, or metabolic syndrome—may harbor subclinical atherosclerosis despite being asymptomatic. Traditional risk calculators often miss high-risk patients who could benefit from early intervention.
The 202302CPC study, sponsored by Cleerly and coordinated by CPC Clinical Research, is a prospective observational trial evaluating how AI-driven coronary computed tomography angiography (CCTA) can be used to identify hidden heart disease in individuals who otherwise show no symptoms. The goal is to enhance primary prevention by providing physicians with a plaque-based, patient-specific cardiovascular risk profile, using Cleerly’s advanced imaging platform.
Inclusion Criteria
Adults aged ≥40 years
Asymptomatic (no history of angina, chest pain, or cardiac events)
Diagnosed with one or more of the following:
Type 2 diabetes
Prediabetes
Metabolic syndrome
No known history of cardiovascular disease (CVD) or revascularization
Eligible for coronary CT angiography (CCTA)
Able and willing to provide informed consent
Exclusion Criteria
Known cardiovascular disease, including previous MI, stroke, or coronary interventions
Symptomatic individuals with chest pain or angina-equivalent symptoms
Contraindications to CCTA (e.g., iodine contrast allergy, renal impairment)
Pregnancy or breastfeeding
Participation in another clinical trial that might interfere with study procedures or data interpretation
Benefits of Participation
No-cost coronary CT angiogram interpreted using Cleerly’s advanced AI technology
Insight into personal cardiovascular risk profile based on coronary plaque burden and distribution
Results shared with participant’s primary care provider for informed decision-making
Close health monitoring throughout participation
Contributing to the development of AI tools for early heart disease detection
Use of Cleerly Imaging AI in Primary Prevention of Cardiovascular Events in At-Risk Asymptomatic Individuals
Site/Study Location
Northridge
Protocol
202302CPC
Trail Details
Cardiovascular disease (CVD) remains the leading cause of death globally, and many at-risk individuals—especially those with Type 2 diabetes, prediabetes, or metabolic syndrome—may harbor subclinical atherosclerosis despite being asymptomatic. Traditional risk calculators often miss high-risk patients who could benefit from early intervention.
The 202302CPC study, sponsored by Cleerly and coordinated by CPC Clinical Research, is a prospective observational trial evaluating how AI-driven coronary computed tomography angiography (CCTA) can be used to identify hidden heart disease in individuals who otherwise show no symptoms. The goal is to enhance primary prevention by providing physicians with a plaque-based, patient-specific cardiovascular risk profile, using Cleerly’s advanced imaging platform.
Inclusion Criteria
Adults aged ≥40 years
Asymptomatic (no history of angina, chest pain, or cardiac events)
Diagnosed with one or more of the following:
Type 2 diabetes
Prediabetes
Metabolic syndrome
No known history of cardiovascular disease (CVD) or revascularization
Eligible for coronary CT angiography (CCTA)
Able and willing to provide informed consent
Exclusion Criteria
Known cardiovascular disease, including previous MI, stroke, or coronary interventions
Symptomatic individuals with chest pain or angina-equivalent symptoms
Contraindications to CCTA (e.g., iodine contrast allergy, renal impairment)
Pregnancy or breastfeeding
Participation in another clinical trial that might interfere with study procedures or data interpretation
Benefits of Participation
No-cost coronary CT angiogram interpreted using Cleerly’s advanced AI technology
Insight into personal cardiovascular risk profile based on coronary plaque burden and distribution
Results shared with participant’s primary care provider for informed decision-making
Close health monitoring throughout participation
Contributing to the development of AI tools for early heart disease detection
Use of Cleerly Imaging AI in Primary Prevention of Cardiovascular Events in At-Risk Asymptomatic Individuals
Site/Study Location
Huntington Park
Protocol
202302CPC
Trail Details
Cardiovascular disease (CVD) remains the leading cause of death globally, and many at-risk individuals—especially those with Type 2 diabetes, prediabetes, or metabolic syndrome—may harbor subclinical atherosclerosis despite being asymptomatic. Traditional risk calculators often miss high-risk patients who could benefit from early intervention.
The 202302CPC study, sponsored by Cleerly and coordinated by CPC Clinical Research, is a prospective observational trial evaluating how AI-driven coronary computed tomography angiography (CCTA) can be used to identify hidden heart disease in individuals who otherwise show no symptoms. The goal is to enhance primary prevention by providing physicians with a plaque-based, patient-specific cardiovascular risk profile, using Cleerly’s advanced imaging platform.
Inclusion Criteria
Adults aged ≥40 years
Asymptomatic (no history of angina, chest pain, or cardiac events)
Diagnosed with one or more of the following:
Type 2 diabetes
Prediabetes
Metabolic syndrome
No known history of cardiovascular disease (CVD) or revascularization
Eligible for coronary CT angiography (CCTA)
Able and willing to provide informed consent
Exclusion Criteria
Known cardiovascular disease, including previous MI, stroke, or coronary interventions
Symptomatic individuals with chest pain or angina-equivalent symptoms
Contraindications to CCTA (e.g., iodine contrast allergy, renal impairment)
Pregnancy or breastfeeding
Participation in another clinical trial that might interfere with study procedures or data interpretation
Benefits of Participation
No-cost coronary CT angiogram interpreted using Cleerly’s advanced AI technology
Insight into personal cardiovascular risk profile based on coronary plaque burden and distribution
Results shared with participant’s primary care provider for informed decision-making
Close health monitoring throughout participation
Contributing to the development of AI tools for early heart disease detection
Use of CAMPSTIM Therapy in Adults With Hard-to-Heal Diabetic Foot Ulcers (DFUs)
Site/Study Location
Northridge
Protocol
CAMPSTIM
Trail Details
Diabetic foot ulcers (DFUs) are a severe complication of diabetes, affecting approximately 15% of people with the condition during their lifetime. DFUs are often resistant to conventional treatments and are associated with high rates of infection, hospitalization, and lower-limb amputation.
The CAMPSTIM study is a clinical trial sponsored by Campstim and conducted by the Serena Group, aiming to evaluate the safety and efficacy of CAMPSTIM, a novel wound healing therapy designed to stimulate tissue regeneration and improve healing outcomes in hard-to-heal diabetic foot ulcers.
Inclusion Criteria
Adults aged 18 years or older
Diagnosed with Type 1 or Type 2 diabetes
Presence of a hard-to-heal diabetic foot ulcer:
Ulcer present for ≥4 weeks
Wound size between defined protocol limits (typically 1–25 cm²)
No signs of active infection or osteomyelitis
Adequate circulation to the affected limb as confirmed by screening tests
Ability to comply with offloading and wound care protocols
Signed informed consent
Exclusion Criteria
Ulcers with active infection, exposed bone, or clinical signs of sepsis
Wounds caused by non-diabetic etiologies (e.g., venous ulcers)
Osteomyelitis at the ulcer site
Immunosuppressive conditions or ongoing chemotherapy
Peripheral arterial disease that limits blood flow severely (based on screening)
Known allergies or adverse reactions to study materials
Pregnant or breastfeeding individuals
Participation in another investigational trial within the past 30 days
Benefits of Participation
Access to an innovative wound care treatment at no cost
Regular monitoring and wound assessments by expert wound care specialists
Support with transportation reimbursement (if applicable)
Potential for improved healing rates compared to standard care
Contributing to research aimed at improving outcomes for people with diabetic woundsAccess to an innovative wound care treatment at no cost
Regular monitoring and wound assessments by expert wound care specialists
Support with transportation reimbursement (if applicable)
Potential for improved healing rates compared to standard care
Contributing to research aimed at improving outcomes for people with diabetic wounds
Use of AstraZeneca’s in Patients With Chronic Kidney Disease and Elevated Proteinuria
Site/Study Location
Tarzana
Protocol
D4325C00010
Trail Details
Chronic Kidney Disease (CKD) affects over 850 million people globally and is a major contributor to cardiovascular morbidity and mortality. High levels of protein in the urine (proteinuria) are both a marker and a driver of kidney damage progression. Despite current therapies like ACE inhibitors and SGLT2 inhibitors, many patients remain at high risk for kidney failure and cardiovascular complications.
The D4325C00010 study, sponsored and conducted by AstraZeneca, is a Phase 3, randomized, double-blind, placebo-controlled clinical trial investigating the effectiveness of a novel investigational therapy in slowing the progression of CKD in adults with high proteinuria.
Inclusion Criteria
Adults aged ≥18 years
Diagnosed with Chronic Kidney Disease (CKD) not requiring dialysis
High proteinuria defined as:
UACR ≥200 mg/g, and
eGFR between 25–75 mL/min/1.73 m²
Stable use of a renin-angiotensin system inhibitor (ACEi or ARB) for at least 4 weeks before screening
Capable of providing written informed consent
Exclusion Criteria
Currently receiving or planning to start dialysis within 3 months
Renal transplant recipients
Type 1 diabetes mellitus
Severe hepatic disease
Active malignancy (with few exceptions)
Pregnancy or breastfeeding
Any condition that may, in the opinion of the investigator, affect safety or study compliance
Benefits of Participation
Access to an investigational medication designed to slow kidney damage progression
Regular health monitoring and laboratory testing at no cost
Support by a qualified nephrology research team
Travel compensation may be available
Contributing to the advancement of kidney disease treatments that may benefit millions
Evaluation of AstraZeneca’s Investigational Treatment in Adults With Chronic Obstructive Pulmonary Disease (COPD)
Site/Study Location
Tarzana
Protocol
D5989C00001
Trail Details
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterized by airflow limitation, chronic inflammation, and frequent exacerbations. It affects an estimated 384 million people globally, and remains a leading cause of morbidity, mortality, and healthcare utilization.
The D5989C00001 trial is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of an investigational therapy in reducing COPD exacerbations and improving lung function in patients with moderate-to-severe COPD, despite standard therapy.
Inclusion Criteria
Adults aged ≥40 years
Confirmed diagnosis of moderate to severe COPD according to GOLD criteria
History of ≥1 moderate or severe COPD exacerbation in the previous 12 months
Current or former smokers with a smoking history of ≥10 pack-years
Receiving stable background COPD therapy (e.g., LAMA/LABA, ICS combinations)
Ability to provide informed consent and comply with study procedures
Exclusion Criteria
Diagnosis of asthma, interstitial lung disease, or other non-COPD pulmonary conditions
Recent respiratory infection or exacerbation within 4 weeks of screening
Hospitalization for COPD within 3 months prior to enrollment
Current use of investigational treatments or participation in other clinical trials
Clinically significant cardiovascular, renal, or hepatic disease
History of lung surgery or lung cancer
Pregnant or breastfeeding individuals
Benefits of Participation
Access to a new potential therapy for COPD at no cost
Comprehensive pulmonary evaluation and regular follow-ups with specialists
Close monitoring for disease progression and exacerbations
Travel reimbursement and/or compensation for time (site-dependent)
Contribution to the development of improved treatments for COPD
AstraZeneca Study Investigational Therapy for Chronic Kidney Disease and Hypertension
Site/Study Location
Tarzana
Protocol
D6972C00003
Trail Details
Chronic Kidney Disease (CKD) and hypertension frequently co-exist and contribute significantly to cardiovascular risk and disease progression. Despite existing treatment options such as ACE inhibitors, ARBs, and SGLT2 inhibitors, many patients continue to experience uncontrolled blood pressure and kidney function decline.
The D6972C00003 trial is a Phase 2 randomized, double-blind, placebo-controlled clinical study conducted by AstraZeneca, evaluating the safety, tolerability, and efficacy of an investigational agent aimed at slowing CKD progression and improving blood pressure control in adults with coexisting CKD and hypertension.
Inclusion Criteria
Adults aged ≥18 years
Diagnosed with Chronic Kidney Disease, defined by:
eGFR between 25–90 mL/min/1.73 m²
Evidence of kidney damage (e.g., elevated albuminuria/proteinuria)
Hypertension diagnosis, with systolic BP ≥130 mmHg despite stable antihypertensive therapy
Stable use of ACEi or ARB for at least 4 weeks
Willing and able to provide written informed consent
Exclusion Criteria
Type 1 diabetes mellitus
Recent hospitalization for heart failure, stroke, or myocardial infarction (within 3 months)
Current dialysis or renal transplant recipients
Significant hepatic impairment
Active malignancy or history of cancer in the past 3 years (except non-melanoma skin cancer)
Pregnancy or breastfeeding
Participation in another investigational study within 30 days
Any other medical condition that may interfere with study safety or compliance, as determined by the investigator
Benefits of Participation
Access to an investigational treatment that may provide better management of CKD and hypertension
Frequent health evaluations, lab monitoring, and follow-up with nephrology specialists
Study medication and care at no cost
Reimbursement for travel or time (site-dependent)
Contributing to medical research that may benefit millions with CKD
AstraZeneca Investigational Therapy for Patients With CKD and Hypertension
Site/Study Location
Tarzana
Protocol
D6972C00002
Trail Details
Chronic Kidney Disease (CKD) and hypertension are tightly interconnected—hypertension both causes and worsens CKD. Managing both conditions effectively is key to slowing disease progression and preventing cardiovascular events. However, many patients remain inadequately controlled on current therapies.
D6972C00002 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial conducted by AstraZeneca, aiming to assess the long-term efficacy and safety of an investigational drug to reduce the progression of CKD and better control blood pressure in adults with coexisting CKD and hypertension.
Inclusion Criteria
Age 18 years or older
Documented CKD (eGFR 25–90 mL/min/1.73 m²) with proteinuria
Diagnosis of hypertension, defined as:
SBP ≥130 mmHg, despite ≥4 weeks of antihypertensive therapy
On stable doses of ACE inhibitors or ARBs
Capable of providing written informed consent
Exclusion Criteria
Dialysis-dependent or renal transplant recipients
Recent cardiovascular events (e.g., MI, stroke, unstable angina) within 3 months
Severe liver disease or hepatic impairment
Diagnosis of Type 1 diabetes
Active or recent cancer (except treated non-melanoma skin cancer)
Participation in another clinical study within 30 days
Pregnant, breastfeeding, or planning pregnancy
Investigator-determined inability to comply with study procedures
Benefits of Participation
Study-related care, labs, and investigational medication at no cost
Enhanced monitoring of kidney function and blood pressure
Access to a potential new treatment before commercial availability
Possible travel or visit compensation
Support from a highly qualified research and nephrology team
Cerium Pharmaceuticals ACTH-PMN-301: Investigational Therapy for Primary Membranous Nephropathy (PMN)
Site/Study Location
Tarzana
Protocol
ACTH-PMN-301
Trail Details
Primary Membranous Nephropathy (PMN) is a rare autoimmune kidney disease characterized by immune complex deposition in the glomerular basement membrane, leading to nephrotic syndrome, proteinuria, and progressive loss of kidney function. Current treatments include immunosuppressive therapies, which may be associated with significant side effects and variable efficacy.
The ACTH-PMN-301 trial is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a long-acting adrenocorticotropic hormone (ACTH) formulation in adults with biopsy-proven PMN. The investigational therapy aims to reduce proteinuria and preserve kidney function in patients with active disease who are at high risk for progression.
Inclusion Criteria
Adults aged 18 to 75 years
Biopsy-confirmed primary membranous nephropathy (PMN)
Urine protein-to-creatinine ratio (UPCR) ≥3.5 g/g on a stable regimen for ≥3 months
eGFR ≥30 mL/min/1.73 m²
Anti-PLA2R antibody positivity (if applicable)
Blood pressure ≤140/90 mmHg on stable treatment
Ability and willingness to provide informed consent
Exclusion Criteria
Secondary MN (e.g., lupus, hepatitis B/C, malignancy-associated)
History of organ transplantation
Current treatment with rituximab, cyclophosphamide, or calcineurin inhibitors within 6 months
Uncontrolled diabetes mellitus (HbA1c >8.5%)
Significant cardiovascular, hepatic, or pulmonary disease
Use of investigational drugs within the past 30 days
Pregnant or breastfeeding individuals
Any condition that may interfere with participation or safety
Benefits of Participation
Access to a novel ACTH therapy that may reduce proteinuria and preserve kidney function
Close monitoring by nephrology specialists
Study-related care and medication provided at no cost
Compensation for time and travel (site-dependent)
Contribution to the development of better treatments for rare kidney diseases
Eli Lilly Study Investigational Therapy for Obesity
Site/Study Location
Tarzana
Protocol
I8F-MC-GPIJ
Trail Details
Obesity is a complex chronic disease associated with significant health risks, including cardiovascular disease, type 2 diabetes, and premature mortality. Despite available interventions, sustained weight management remains a challenge for many patients.
Study I8F-MC-GPIJ is a Phase 3, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a novel GLP-1 receptor agonist for the treatment of obesity in adults with or without comorbidities. The investigational drug is part of Lilly’s advanced metabolic pipeline, aimed at promoting clinically meaningful weight loss and improving metabolic health outcomes.
Inclusion Criteria
Adults aged 18 years or older
BMI ≥27 kg/m² with comorbidities or BMI ≥30 kg/m² without comorbidities
Stable weight (±5%) for at least 3 months prior to screening
Willing to follow a reduced-calorie diet and increased physical activity
Provide informed consent and able to comply with study protocol
Exclusion Criteria
Diagnosis of type 1 diabetes mellitus
Use of anti-obesity medication or GLP-1 receptor agonists within the past 3 months
History of pancreatitis, medullary thyroid carcinoma, or MEN2 syndrome
Uncontrolled psychiatric illness or active substance abuse
Recent bariatric surgery or planned surgery during the study period
Pregnant, planning pregnancy, or breastfeeding
Participation in another clinical trial within the last 30 days
Benefits of Participation
Access to a cutting-edge obesity treatment potentially prior to market approval
Regular follow-up and personalized care from obesity-focused clinical experts
Study-related investigational medication and lab testing at no cost
Possible travel reimbursements and compensation
Contributing to advancements in obesity management
Eli Lilly Study Investigational Therapy for Obesity
Site/Study Location
Huntington Park
Protocol
I8F-MC-GPIJ
Trail Details
Obesity is a complex chronic disease associated with significant health risks, including cardiovascular disease, type 2 diabetes, and premature mortality. Despite available interventions, sustained weight management remains a challenge for many patients.
Study I8F-MC-GPIJ is a Phase 3, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a novel GLP-1 receptor agonist for the treatment of obesity in adults with or without comorbidities. The investigational drug is part of Lilly’s advanced metabolic pipeline, aimed at promoting clinically meaningful weight loss and improving metabolic health outcomes.
Inclusion Criteria
Adults aged 18 years or older
BMI ≥27 kg/m² with comorbidities or BMI ≥30 kg/m² without comorbidities
Stable weight (±5%) for at least 3 months prior to screening
Willing to follow a reduced-calorie diet and increased physical activity
Provide informed consent and able to comply with study protocol
Exclusion Criteria
Diagnosis of type 1 diabetes mellitus
Use of anti-obesity medication or GLP-1 receptor agonists within the past 3 months
History of pancreatitis, medullary thyroid carcinoma, or MEN2 syndrome
Uncontrolled psychiatric illness or active substance abuse
Recent bariatric surgery or planned surgery during the study period
Pregnant, planning pregnancy, or breastfeeding
Participation in another clinical trial within the last 30 days
Benefits of Participation
Access to a cutting-edge obesity treatment potentially prior to market approval
Regular follow-up and personalized care from obesity-focused clinical experts
Study-related investigational medication and lab testing at no cost
Possible travel reimbursements and compensation
Contributing to advancements in obesity management
Eli Lilly Study Investigational Therapy for Obesity and Related Cardiometabolic Conditions
Site/Study Location
Tarzana
Protocol
Trail Details
Obesity is not only a standalone chronic disease but also a major contributing factor to serious health conditions like atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). These comorbidities compound health risks and significantly elevate morbidity and mortality rates in affected individuals.
Study J1I-MC-GZBO is a Phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trial sponsored by Eli Lilly and Company. The trial investigates the efficacy and safety of a next-generation metabolic therapy targeting sustained weight reduction, while also evaluating its impact on cardiovascular and renal outcomes in adults diagnosed with obesity and either ASCVD, CKD, or both.
Inclusion Criteria
Adults aged 18 years and older
BMI ≥27 kg/m² with at least one of the following:
Clinically documented ASCVD
Diagnosed CKD with eGFR ≥30 mL/min/1.73 m²
Stable medical therapy for ASCVD and/or CKD for at least 3 months
Willingness to follow a standardized diet and lifestyle plan
Ability to provide informed consent
Exclusion Criteria
Diagnosis of type 1 diabetes or uncontrolled type 2 diabetes (HbA1c >10%)
Recent cardiovascular event (e.g., myocardial infarction, stroke) within the past 90 days
History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2)
Active liver disease (e.g., ALT or AST >3x ULN)
Use of other weight loss medications or GLP-1 receptor agonists within 90 days
Recent bariatric surgery or planned surgery during the trial
Pregnancy or breastfeeding
Participation in another investigational study within the past 30 days
Benefits of Participation
Access to a potentially groundbreaking therapy for obesity, ASCVD, and CKD
Comprehensive medical oversight from experienced clinical investigators
No-cost study medication, labs, and medical evaluations
Travel reimbursement and participant compensation (site-dependent)
Direct contribution to advancing treatments for complex cardiometabolic diseases
Pathalys Pharma Study Investigational Treatment for Secondary Hyperparathyroidism (SHPT) in End-Stage Kidney Disease (ESKD) Patients on Hemodialysis
Site/Study Location
Tarzana
Protocol
PP3003
Trail Details
Secondary Hyperparathyroidism (SHPT) is a common and serious complication of End-Stage Kidney Disease (ESKD), especially among patients undergoing maintenance hemodialysis. SHPT results from imbalances in calcium, phosphorus, and vitamin D metabolism due to impaired kidney function, leading to elevated parathyroid hormone (PTH) levels, bone disease, and cardiovascular complications.
The PP3003 study is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of an investigational therapy developed by Pathalys Pharma. This treatment aims to reduce elevated PTH levels in patients with SHPT who are receiving chronic hemodialysis.
Inclusion Criteria
Adults aged ≥18 years
Diagnosed with End-Stage Kidney Disease (ESKD) and undergoing stable hemodialysis (3x/week) for ≥3 months
Documented Secondary Hyperparathyroidism (SHPT) with:
Screening iPTH ≥600 pg/mL
Stable doses of vitamin D analogs, phosphate binders, and/or calcimimetics (if applicable) for at least 2–4 weeks prior to screening
Ability and willingness to provide informed consent
Exclusion Criteria
History of parathyroidectomy
Recent (within 4 weeks) hospitalization for cardiovascular instability
Active liver disease or significant hepatic impairment
Calcium or phosphorus levels outside protocol-specified limits
Use of investigational drugs within 30 days prior to screening
Known hypersensitivity to the study drug or its components
Pregnancy or breastfeeding
Any medical or psychiatric condition that may interfere with study participation or data reliability, per investigator’s judgment
Benefits of Participation
Access to a novel therapy for SHPT that may reduce the need for surgical intervention or high-dose medications
No-cost medical evaluations, labs, and study medication
Close monitoring by nephrology research experts
Travel reimbursement and compensation (varies by site)
Contribute to critical advancements in treatment for patients with ESKD and SHPT
Chronic Kidney Disease (CKD) affects over 850 million people globally and is a major contributor to cardiovascular morbidity and mortality. High levels of protein in the urine (proteinuria) are both a marker and a driver of kidney damage progression. Despite current therapies like ACE inhibitors and SGLT2 inhibitors, many patients remain at high risk for kidney failure and cardiovascular complications. The study, sponsored and conducted by AstraZeneca, is a Phase 3, randomized, double-blind, placebo-controlled clinical trial investigating the effectiveness of a novel investigational therapy in slowing the progression of CKD in adults with high proteinuria.
Site/Study Location
Huntington Park
Protocol
D4325C00010
Trail Details
Adults aged ≥18 years
Diagnosed with Chronic Kidney Disease (CKD) not requiring dialysis
High proteinuria defined as:
UACR ≥200 mg/g, and
eGFR between 25–75 mL/min/1.73 m²
Stable use of a renin-angiotensin system inhibitor (ACEi or ARB) for at least 4 weeks before screening
Capable of providing written informed consent
Inclusion Criteria
Currently receiving or planning to start dialysis within 3 months
Renal transplant recipients
Type 1 diabetes mellitus
Severe hepatic disease
Active malignancy (with few exceptions)
Pregnancy or breastfeeding
Any condition that may, in the opinion of the investigator, affect safety or study compliance
Exclusion Criteria
Access to an investigational medication designed to slow kidney damage progression
Regular health monitoring and laboratory testing at no cost
Support by a qualified nephrology research team
Travel compensation may be available
Contributing to the advancement of kidney disease treatments that may benefit millions
Benefits of Participation
Access to an investigational therapy that may offer renal protective benefits
No-cost study medication, laboratory testing, and medical exams
Ongoing monitoring by experienced clinical research professionals
Potential early detection and management of worsening kidney function
Travel support and participant compensation (site dependent)
Chinook Therapeutics Study Investigational Therapy for Immunoglobulin A Nephropathy (IgAN)
Site/Study Location
Huntington Park
Protocol
CHK02-02
Trail Details
Immunoglobulin A Nephropathy (IgAN), also known as Berger’s disease, is a chronic kidney disorder caused by deposits of the IgA antibody in the glomeruli, leading to inflammation and progressive kidney damage. IgAN is one of the most common forms of glomerulonephritis and can result in end-stage kidney disease (ESKD) in a significant proportion of patients.
Study CHK02-02 is a Phase 2/3 clinical trial evaluating the safety, efficacy, and tolerability of a novel investigational therapy developed by Chinook Therapeutics. The study drug aims to reduce proteinuria and preserve renal function in patients with biopsy-confirmed IgAN who are at high risk of disease progression.
Inclusion Criteria
Age 18 to 75 years
Biopsy-confirmed diagnosis of primary IgA nephropathy
Proteinuria ≥1 g/day despite optimized supportive care (e.g., stable RAAS blockade)
eGFR ≥30 mL/min/1.73m²
Stable treatment with ACE inhibitors or ARBs for at least 12 weeks prior to screening
Willing and able to provide informed consent
Exclusion Criteria
Access to an innovative investigational therapy specifically targeting IgAN progression
No-cost study drug, lab work, imaging, and clinical assessments
Close monitoring by board-certified nephrologists and research professionals
Compensation for travel and time (based on site policy)
Potential for delayed kidney function decline and improved quality of life
Benefits of Participation
Access to an innovative investigational therapy specifically targeting IgAN progression
No-cost study drug, lab work, imaging, and clinical assessments
Close monitoring by board-certified nephrologists and research professionals
Compensation for travel and time (based on site policy)
Potential for delayed kidney function decline and improved quality of life
Areteria Therapeutics Study Investigational Therapy for Severe Eosinophilic Asthma
Site/Study Location
Northridge
Protocol
AR-DEX-22-02
Trail Details
Severe eosinophilic asthma is a subtype of asthma characterized by elevated eosinophils, a type of white blood cell that contributes to airway inflammation, hyperresponsiveness, and frequent exacerbations. Patients with this condition often remain symptomatic despite high-dose inhaled corticosteroids and additional controller therapies.
The AR-DEX-22-02 study is a Phase 2 clinical trial evaluating the safety, efficacy, and pharmacodynamics of an investigational biologic targeting eosinophil-mediated pathways in patients with severe eosinophilic asthma. The investigational product may help reduce exacerbation frequency, improve lung function, and decrease the requirement for oral corticosteroids.
Inclusion Criteria
Age 18 to 75 years
Documented diagnosis of asthma for ≥12 months
History of ≥2 exacerbations in the past 12 months requiring systemic corticosteroids
Blood eosinophil count ≥300 cells/μL at screening or documented within the last 12 months
Treatment with high-dose inhaled corticosteroids + additional controller(s)
Pre-bronchodilator FEV₁ <80% of predicted normal
Willingness to discontinue other investigational agents
Able to provide written informed consent
Exclusion Criteria
Diagnosis of other pulmonary diseases (e.g., COPD, bronchiectasis)
Current smoking or >10 pack-year smoking history
Recent respiratory infections (within 4 weeks of screening)
Previous treatment with anti-IL-5, anti-IL-4/13, or anti-IgE biologics within protocol-specified washout periods
Known immunodeficiency or active infection (e.g., TB, Hep B/C, HIV)
Pregnancy or lactation
History of anaphylaxis or severe drug allergies
Participation in another investigational study within the last 30 days
Any condition that, in the investigator’s opinion, may pose a risk or interfere with study outcomes
Benefits of Participation
Access to a novel biologic therapy that may provide better asthma control
No-cost study medication, procedures, and testing
Frequent monitoring and assessments by an experienced clinical team
Compensation for time and travel may be provided
Potential improvement in symptom control, exacerbation rates, and quality of life
Areteria Therapeutics Study Investigational Biologic for Severe Eosinophilic Asthma
Site/Study Location
Northridge
Protocol
AR-DEX-23-05
Trail Details
Severe eosinophilic asthma is a chronic inflammatory condition characterized by persistent airway inflammation due to elevated eosinophils. Patients frequently experience exacerbations, poor asthma control, and reduced quality of life despite high-dose inhaled corticosteroids and additional controller medications.
The AR-DEX-23-05 trial is a Phase 2b/3 randomized, double-blind, placebo-controlled study evaluating a next-generation biologic developed by Areteria Therapeutics. The investigational therapy targets interleukin-mediated pathways involved in eosinophilic inflammation and aims to reduce exacerbation frequency, improve lung function, and enhance asthma control.
The study is expected to begin enrollment in 2025 and is managed in collaboration with Parexel as the clinical research organization. It will include adult patients with inadequately controlled severe eosinophilic asthma.
Inclusion Criteria
Adults aged ≥18 years
Diagnosed with End-Stage Kidney Disease (ESKD) and undergoing stable hemodialysis (3x/week) for ≥3 months
Documented Secondary Hyperparathyroidism (SHPT) with:
Screening iPTH ≥600 pg/mL
Stable doses of vitamin D analogs, phosphate binders, and/or calcimimetics (if applicable) for at least 2–4 weeks prior to screening
Ability and willingness to provide informed consent
Exclusion Criteria
Other significant pulmonary conditions (e.g., COPD, cystic fibrosis)
Current smoker or use of tobacco/nicotine products within the last 6 months
Use of biologic therapies targeting IL-5, IL-4/13, or IgE within protocol-specified washout periods
Active or chronic infectious disease, including TB, hepatitis B/C, or HIV
Pregnant or breastfeeding women
Recent hospitalization due to asthma within 4 weeks prior to screening
Participation in another interventional study within the past 30 days
Any other condition that, in the investigator’s opinion, could interfere with safety or study outcomes
Benefits of Participation
Access to cutting-edge biologic treatment for severe asthma at no cost
Extensive monitoring by a dedicated asthma research team
Potential improvements in asthma symptoms, exacerbation frequency, and lung function
Compensation for time and travel
Participants receive comprehensive pulmonary evaluations throughout the study
STABLECAMP Study: Evaluation of Advanced Therapy in Chronic Wounds Including Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs)
Site/Study Location
Huntington Park
Protocol
STABLECAMP
Trail Details
Chronic wounds, including Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs), are major health burdens linked to prolonged healing, infection, and in severe cases, limb amputation. They are especially common in patients with diabetes and venous insufficiency and are challenging to manage with standard care alone.
The STABLECAMP study is a prospective, controlled clinical trial designed to evaluate the safety and efficacy of a novel regenerative therapy intended to promote healing in hard-to-heal chronic wounds. The investigational therapy may enhance tissue regeneration, reduce inflammation, and accelerate wound closure.
Inclusion Criteria
Adults ≥18 years of age
Presence of a chronic DFU or VLU that has not healed with standard care for at least 4 weeks
Adequate circulation to the affected limb, confirmed by vascular assessment
Willingness to comply with study visits and protocol
Written informed consent provided
Exclusion Criteria
Infected wounds or presence of osteomyelitis at the ulcer site
Wounds with exposed bone, tendon, or joint capsule
Use of investigational wound care therapies within the past 30 days
Significant uncontrolled comorbidities, including active malignancy or severe peripheral arterial disease
Pregnant or breastfeeding women
Any condition that, in the opinion of the investigator, may interfere with the study outcomes or participant safety
Benefits of Participation
Access to advanced investigational therapy for chronic wound healing at no cost
Comprehensive wound care assessments by a specialized team
Monitoring by experienced clinicians throughout the trial
Potential for improved healing outcomes
Compensation for time and travel may be offered
Chronic Kidney Disease (CKD) affects over 850 million people globally and is a major contributor to cardiovascular morbidity and mortality. High levels of protein in the urine (proteinuria) are both a marker and a driver of kidney damage progression. Despite current therapies like ACE inhibitors and SGLT2 inhibitors, many patients remain at high risk for kidney failure and cardiovascular complications. The study, sponsored and conducted by AstraZeneca, is a Phase 3, randomized, double-blind, placebo-controlled clinical trial investigating the effectiveness of a novel investigational therapy in slowing the progression of CKD in adults with high proteinuria.
Site/Study Location
Northridge
Protocol
D4325C00010
Trail Details
Adults aged ≥18 years
Diagnosed with Chronic Kidney Disease (CKD) not requiring dialysis
High proteinuria defined as:
UACR ≥200 mg/g, and
eGFR between 25–75 mL/min/1.73 m²
Stable use of a renin-angiotensin system inhibitor (ACEi or ARB) for at least 4 weeks before screening
Capable of providing written informed consent
Inclusion Criteria
Currently receiving or planning to start dialysis within 3 months
Renal transplant recipients
Type 1 diabetes mellitus
Severe hepatic disease
Active malignancy (with few exceptions)
Pregnancy or breastfeeding
Any condition that may, in the opinion of the investigator, affect safety or study compliance
Exclusion Criteria
Access to an investigational medication designed to slow kidney damage progression
Regular health monitoring and laboratory testing at no cost
Support by a qualified nephrology research team
Travel compensation may be available
Contributing to the advancement of kidney disease treatments that may benefit millions
Benefits of Participation
Access to cutting-edge biologic treatment for severe asthma at no cost
Extensive monitoring by a dedicated asthma research team
Potential improvements in asthma symptoms, exacerbation frequency, and lung function
Compensation for time and travel
Participants receive comprehensive pulmonary evaluations throughout the study
